This inventor holds 1 USPTO granted patent. Top assignee: Obi Pharma Inc.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Innovations in Glycoprotein Engineering by Pu-Ling Hu
Introduction
Pu-Ling Hu is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of glycoprotein engineering through his innovative research and development of glycosynthase enzymes. His work has implications for the enhancement of antibody therapies, which are crucial in modern medicine.
Latest Patents
Pu-Ling Hu holds a patent for "Glycosynthase variants for glycoprotein engineering and methods of use." This patent describes novel glycosynthase enzymes, specifically EndoSd-D232M and EndoSz-D234M, which possess glycan conjugation and modification activities. These enzymes target the conserved N297 glycosylation site of the Fc region of antibodies, enabling advancements in antibody remodeling. The glycosynthase activities of these variants have been successfully applied to various monoclonal antibodies (mAbs) that target different receptors, including Globo H, SSEA-4, and Herceptin.
Career Highlights
Pu-Ling Hu is associated with Obi Pharma Inc., where he continues to push the boundaries of glycoprotein engineering. His research has demonstrated that the remodeled homogeneous antibody, mAb-G2S2, exhibits increased relative activity, ranging from 3 to 26 folds in ADCC assays. This advancement highlights the potential of his inventions in improving therapeutic antibodies.
Collaborations
Pu-Ling Hu has collaborated with notable colleagues, including Teng-Yi Huang and Yi-Chien Tsai. Their combined expertise has contributed to the successful development of innovative glycosynthase enzymes and their applications in antibody therapies.
Conclusion
Pu-Ling Hu's work in glycoprotein engineering represents a significant advancement in the field of biotechnology. His innovative patents and collaborations are paving the way for improved therapeutic options in medicine.